IL6 and COVID-19: In light of these findings, it was proposed that IL‐6 blockers, such as sarilumab, siltuximab and tocilizumab, and IL‐1β receptor blocker can have therapeutic efficacy in treating severe cases of COVID‐19 patients to resolve hyperinflammation and control the propagation of the pathological immune response to virus infection.78, 81, 82